Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer

European Journal of Cancer

Volumn 49, Issue 6, 2013, Pages 1246-1253

  Tan, David S P ^a   Yap, Timothy A ^a   Hutka, Margaret ^b   Roxburgh, Patricia ^c,d   Ang, Jooern ^a   Banerjee, Susana ^a   Grzybowska, Ewa ^b   Gourley, Charlie ^e   Gore, Martin E ^a   Kaye, Stan B ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

BRCA1; BRCA2; Ovarian cancer; Paclitaxel; Resistance; Response; Taxane

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; DNA METHYLATION; DRUG EFFICACY; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MONOTHERAPY; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRCA1 PROTEIN; BRCA2 PROTEIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OUTCOME ASSESSMENT (HEALTH CARE); OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84875727912     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.016     Document Type: Article

References (28)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. T.A. Yap, C.P. Carden, and S.B. Kaye Beyond chemotherapy: targeted therapies in ovarian cancer Nat Rev Cancer 9 2009 167 181
3. J.C. Pavelka, A.J. Li, and B.Y. Karlan Hereditary ovarian cancer-assessing risk and prevention strategies Obstet Gynecol Clin North Am 34 2007 651 665 vii-viii
4. A. Ashworth A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol 26 2008 3785 3790
5. A.A. Jazaeri Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease Mol Oncol 3 2009 151 156
6. R.F. Ozols Paclitaxel plus carboplatin in the treatment of ovarian cancer Semin Oncol 26 1999 84 89
7. T. Pal, J. Permuth-Wey, and R. Kapoor Improved survival in BRCA2 carriers with ovarian cancer Fam Cancer 6 2007 113 119
8. I. Cass, R.L. Baldwin, and T. Varkey Improved survival in women with BRCA-associated ovarian carcinoma Cancer 97 2003 2187 2195
9. D.S. Tan, C. Rothermundt, and K. Thomas "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations J Clin Oncol 26 2008 5530 5536
10. K.L. Bolton, G. Chenevix-Trench, and C. Goh Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer JAMA 307 2012 382 390
11. J.E. Quinn, J.E. Carser, and C.R. James BRCA1 and implications for response to chemotherapy in ovarian cancer Gynecol Oncol 113 2009 134 142
12. P. Tagliaferri, M. Ventura, and F. Baudi BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality? J Ovarian Res 2 2009 14
13. J.E. Quinn, C.R. James, and G.E. Stewart BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy Clin Cancer Res 13 2007 7413 7420
14. P. Tassone, P. Tagliaferri, and A. Perricelli BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells Br J Cancer 88 2003 1285 1291
15. C. Chabalier, C. Lamare, and C. Racca BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance Cell Cycle 5 2006 1001 1007
16. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
17. R.D. Baird, D.S. Tan, and S.B. Kaye Weekly paclitaxel in the treatment of recurrent ovarian cancer Nat Rev Clin Oncol 7 2010 575 582
18. C. Zhou, J.L. Smith, and J. Liu Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1 Oncogene 22 2003 2396 2404
19. V. Sylvain, S. Lafarge, and Y.J. Bignon Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line Int J Oncol 20 2002 845 853
20. E.A. Eisenhauer, W.W. Ten Bokkel Huinink, and K.D. Swenerton European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion J Clin Oncol 12 1994 2654 2666
21. S.L. Edwards, R. Brough, and C.J. Lord Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 2008 1111 1115
22. W.B. Dalton, M.O. Nandan, R.T. Moore, and V.W. Yang Human cancer cells commonly acquire DNA damage during mitotic arrest Cancer Res 67 2007 11487 11492
23. E.A. Stronach, M. Chen, and E.N. Maginn DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance Neoplasia 13 2011 1069 1080
24. M. Fraser, T. Bai, and B.K. Tsang Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function Int J Cancer 122 2008 534 546
25. G.A. Orr, P. Verdier-Pinard, H. McDaid, and S.B. Horwitz Mechanisms of Taxol resistance related to microtubules Oncogene 22 2003 7280 7295
26. A.A. Ahmed, A.D. Mills, and A.E. Ibrahim The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel Cancer Cell 12 2007 514 527
27. J.L. Hilton, J.P. Geisler, and J.A. Rathe Inactivation of BRCA1 and BRCA2 in ovarian cancer J Natl Cancer Inst 94 2002 1396 1406
28. D. Bell, A. Berchuck, and M. Birrer Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615